항균 성분 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the antimicrobial ingredients market size is expected to increase from USD 11.70 billion in 2025 to USD 12.40 billion in 2026 and reach USD 16.60 billion by 2031, growing at a CAGR of 5.99% over 2026-2031.

This report is Segmented by Ingredient Type (Inorganic/Metal-based, Synthetic Organics, Organic Acids & Salts, and More), Application (Medical Devices, Surfaces, Wound Care, Textiles, Disinfectants, Pharma Manufacturing, Others), Form (Powder, Liquid, Gel, Masterbatch, Encapsulated Systems), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts are in Value (USD).

Global Antimicrobial Ingredients Market Trends and Insights

Rising Healthcare-Associated Infections

Healthcare-associated infections impose USD 28 billion to USD 45 billion in annual costs on U.S. hospitals and still affect roughly 1 in 31 patients on any given day. Although bloodstream and urinary-tract infection rates declined modestly between 2023 and 2024, absolute incidence remains high, steering administrators toward catheters, ventilator tubing, and bed linens impregnated with silver and quaternary ammonium compounds. Medicare payment penalties under the Hospital-Acquired Condition Reduction Program further motivate adoption. Peer-reviewed studies show copper-silver textiles retain 99.9% efficacy against ESKAPE pathogens after 50 wash cycles, reinforcing return-on-investment arguments.

Stringent Infection Control Regulations

The FDA's 2024 guidance requires any device marketed with an infection-prevention claim to demonstrate clinical efficacy under ISO 22196 or ASTM E2180. In the EU, the Biocidal Products Regulation demands nanomaterial-specific dossiers that can take five years to clear. These hurdles raise the cost of market entry but also reward suppliers that offer turnkey regulatory files across multiple jurisdictions. To meet both safety and efficacy targets, manufacturers turn to controlled-release capsules that deliver steady antimicrobial levels while limiting cytotoxic peaks. EPA registration of copper-alloy touch surfaces in 2023 exemplifies how material advances and dossier depth intersect.

Regulatory and Safety Concerns

EU dossiers for nanomaterials can cost EUR 1 million per active substance and extend launch cycles to five years. FDA guidance denies accelerated reviews for combination products that claim antimicrobial benefits, forcing full 510(k) or PMA submissions. Hospitals, therefore, hedge with legacy alcohols and chlorine because decades of toxicology data exist. Cytotoxic thresholds also cap silver loading in wound dressings at 10 ppm, limiting efficacy windows and prompting some buyers to stick with cheaper single-use gauze.

Other drivers and restraints analyzed in the detailed report include:

1. Growth in Medical Device and Implant Usage
2. Expansion of Hospital Infrastructure
3. Risk of Antimicrobial Resistance

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, inorganic and metal chemistries captured 38.10% revenue as silver and copper delivered broad-spectrum kill without fostering quick resistance. Copper alloys achieve a 4-log reduction of MRSA within two hours, driving uptake on bed rails and call buttons. Synthetic organics such as quaternary ammonium compounds remain workhorses in sprays and wipes but face eco-toxicity scrutiny. Natural and bio-based options are growing at 7.89% CAGR, supported by sustainability mandates and patient preference for low-toxicity rooms. Essential oils appeal in low-risk zones, while chitosan serves wound dressings needing hemostasis and antimicrobial action. High peptide prices confine their use to premium implants, yet regulatory fast-tracks for GRAS ingredients like nisin could offset cost barriers by 2028.

Surging R&D dollars are steering toward enzymes that disrupt biofilms rather than kill planktonic cells, reducing resistance pressure. DSM-Firmenich is piloting Delvo Nis peptide coatings for catheters, betting that FDA familiarity with the molecule in food applications will streamline device approval.

Geography Analysis

Asia Pacific accounted for 35.18% revenue in 2025, underpinned by China's device factories and India's hospital build-out. Beijing's 14th Five-Year Plan channeled USD 170 billion into provincial facilities, each specifying antimicrobial epoxy floors and copper-alloy handles. Japan obliges antimicrobial coatings on public hospital fixtures, making it a high-value niche despite slower population growth. South Korea enforces JIS Z 2801 testing, which smaller suppliers often lack, giving incumbents an edge.

North America is the quickest-growing geography at 7.67% CAGR because CMS links reimbursement to infection scores. U.S. hospitals willingly pay List N premiums for disinfectants that guarantee SARS-CoV-2 efficacy. Device makers also rely on antimicrobial masterbatch to secure 510(k) clearance for coated catheters. Canada's alignment under USMCA reduces dossier duplication, helping mid-sized formulators expand. Though volumes lag Asia, higher average selling prices deliver outsized profit, reinforcing regional importance to the antimicrobial ingredients market.

Europe, the Middle East, and South America fill the remainder. EU BPR timelines stretch launch cycles, but Germany, France, and the U.K. remain innovation hubs demanding data-rich dossiers. Middle-East bed growth under Vision 2030 stipulates ISO 14644 clean zones, a tailwind for antimicrobial HVAC coatings. South America lags because of budget constraints, yet Mercosur's work on unified biocide rules could shorten approval windows and unlock demand in Brazil and Argentina before 2031.

1. Arxada
2. Ashland
3. Avient Corporation
4. BASF
5. BioCote Limited
6. Celanese
7. Clariant AG
8. Corbion
9. Croda International
10. Dow Inc.
11. DSM-Firmenich
12. Evonik Industries
13. International Flavors & Fragrances (IFF)
14. Kerry Group
15. Lanxess AG
16. Microban International
17. Milliken & Company
18. Novonesis
19. RTP Company
20. Sanitized AG
21. Schulke & Mayr GmbH
22. Sharon Laboratories
23. Symrise
24. THOR Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Healthcare-Associated Infections (HAIs)
  • 4.2.2 Stringent Infection Control Regulations
  • 4.2.3 Growth in Medical Device and Implant Usage
  • 4.2.4 Expansion of Hospital Infrastructure and Healthcare Access
  • 4.2.5 Increased Focus on Surface Hygiene Post-Pandemic
  • 4.2.6 Advancements in Antimicrobial Technologies
• 4.3 Market Restraints
  • 4.3.1 Regulatory and Safety Concerns
  • 4.3.2 Risk of Antimicrobial Resistance (AMR)
  • 4.3.3 High Cost of Advanced Antimicrobial Materials
  • 4.3.4 Limited Long-Term Efficacy and Durability Concerns
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Ingredient Type
  • 5.1.1 Inorganic/metal-based
  • 5.1.2 Synthetic organics
  • 5.1.3 Organic acids & salts
  • 5.1.4 Natural/bio-based
  • 5.1.5 Enzymatic & antimicrobial peptides
• 5.2 By Application
  • 5.2.1 Medical Devices & Implants
  • 5.2.2 Healthcare Surfaces & Coatings
  • 5.2.3 Wound Care Products
  • 5.2.4 Healthcare Textiles
  • 5.2.5 Hospital Hygiene & Disinfectants
  • 5.2.6 Pharmaceutical & Biotechnology Manufacturing
  • 5.2.7 Others
• 5.3 By Form
  • 5.3.1 Dry / Powder
  • 5.3.2 Liquid
  • 5.3.3 Gel / Foam
  • 5.3.4 Masterbatch / Carrier for polymers
  • 5.3.5 Encapsulated / Controlled-release systems
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Arxada
  • 6.3.2 Ashland
  • 6.3.3 Avient Corporation
  • 6.3.4 BASF SE
  • 6.3.5 BioCote Limited
  • 6.3.6 Celanese
  • 6.3.7 Clariant AG
  • 6.3.8 Corbion
  • 6.3.9 Croda International
  • 6.3.10 Dow Inc.
  • 6.3.11 DSM-Firmenich
  • 6.3.12 Evonik Industries
  • 6.3.13 International Flavors & Fragrances (IFF)
  • 6.3.14 Kerry Group
  • 6.3.15 Lanxess AG
  • 6.3.16 Microban International
  • 6.3.17 Milliken & Company
  • 6.3.18 Novonesis
  • 6.3.19 RTP Company
  • 6.3.20 Sanitized AG
  • 6.3.21 Schulke & Mayr GmbH
  • 6.3.22 Sharon Laboratories
  • 6.3.23 Symrise
  • 6.3.24 THOR Group

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment